Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Michaela Harter¹, Rebecca Hetrick², James Slaven³ and Martha Rodriguez⁴, ¹Indiana University School of Medicine, Indianapolis, IN, ²Indiana University School of Medicine, Zionsville, IN, ³Indiana University School of Medicine, Indianapolis, ⁴Riley Hospital For Children At Indiana University, Carmel, IN
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…
Abstract Number: 2407 • ACR Convergence 2025
Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
Jorge Juan Fragío Gil¹, Roxana González Mazario², Pablo Martínez Calabuig³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Isabel Martínez Cordellat⁴, Juan José Lerma Garrido⁴ and Cristina Campos Fernández⁵, ¹Hospital General Universitario, Valencia, Spain, ²Hospital General de Valencia, Valencia, Spain, ³Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁵Hospital General de Valencia, Valencia
Background/Purpose: One common and clinically important form of systemic lupus erythematosus (SLE) is neuropsychiatric systemic lupus erythematosus (NPSLE). This systematic review and meta-analysis aimed to…
Abstract Number: 2390 • ACR Convergence 2025
SLE Genetic Risk Loci in the Context of Environmental Exposure: A Gene-Based Classification and Clinical Insight
Nina Oparina¹, Holme Vestin¹, Sarah Reid¹, Ahmne Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Øyvind Molberg³, Solbritt Rantapää-Dahlqvist⁵, Anna Rudin⁶, Chrisopher Sjöwall⁷, Anders Bengtsson⁴, Lars Rönnblom¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁷Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden
Background/Purpose: Growing evidence supports the role of chemical exposures as contributors to the development of Systemic lupus erythematosus (SLE)1. Several of the gene variants associated…
Abstract Number: 2224 • ACR Convergence 2025
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Seemal Faisal¹, Alexandra Anderson², Luke Sharrock³, James Tran⁴ and Milena Vukelic⁵, ¹Louisiana State University Health Science Center New Orleans, New Orleans, ²Louisiana State University Health Science Center New Orleans, Phoenix, AZ, ³Louisiana State University Health Science Center, New Orleans, LA, ⁴Louisiana State University Health Science Center, New Orleans, ⁵Rheumatology Fellowship Program Director Louisiana State University, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased risk of placental insufficiency and adverse pregnancy outcomes, even when the disease is clinically quiescent.…
Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Hannah Concannon¹, Jasmine Oesch², Sara Mazzarelli², Anne Fields², Keisha-Gaye O'Garo² and Rebecca Sadun³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…
Abstract Number: 1896 • ACR Convergence 2025
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
Jeong Yee¹, Emily Oakes², Candace Feldman³ and Karen H. Costenbader⁴, ¹Sungkyunkwan University, Suwon, MA, South Korea, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Electronic cigarettes, or e-cigarettes, are inhalable aerosol nicotine-delivery devices increasingly used in addition or in place of cigarettes. Cigarette smoking is strongly associated with…
Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Mariana Jiménez Tirado¹, karina santana², Jiram Torres Ruiz³, Jennifer Tiaré Balderas Miranda⁴, Diana Gómez-Martín⁵, José Carlos Páez Franco⁶, Nancy R Mejía Domínguez⁷, Hilda Sánchez Vidal⁶ and Imelda Cecilia Zarzoza Mendoza⁸, ¹Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Ciudad de México, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico, ⁴Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁵INCMNSZ, Mexico city, Federal District, Mexico, ⁶Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, ⁷Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁸Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
Abstract Number: 1761 • ACR Convergence 2025
The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
Juan Liang¹, Yinlian Zhang², Feng Li², Yingfeng Huang³, Ruixia Zhang³ and Ruixue Dai³, ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic), ³CytoCares, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by the production of autoantibodies targeting nuclear antigens, immune complex deposition, and chronic inflammation…
Abstract Number: 1698 • ACR Convergence 2025
X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
Desire Casares Marfil¹, Gülşah Kavrul Kayaalp², Vafa Guliyeva², Özlem Akgün², Şeyma Türkmen³, Elif Kilic Konte⁴, Sezgin Sahin⁴, Ozgur Kasapcopur⁵, Betul Sozeri⁶, Selçuk Sözer Tokdemir⁷, Nuray Aktay Ayaz⁸ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Istanbul University Faculty of Medicine, Istanbul, Turkey, ³University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁶Health sciences university, Istanbul, Turkey, ⁷Istanbul University, Istanbul, Turkey, ⁸Istanbul University Medical School, Istanbul, Turkey
Background/Purpose: DNA methylation plays a critical role in the pathogenesis of lupus. Although most epigenetic studies have focused on autosomal regions, the X chromosome remains…
Abstract Number: 1551 • ACR Convergence 2025
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Zahi Touma¹, Christopher Saffore², Karim Masri³, Jerry Clewell³, Emily Goddard⁴, Grace O'Neill⁴, Madelane Foxall⁴ and Karen H. Costenbader⁵, ¹University of Toronto, Toronto, ON, Canada, ²AbbVie Inc., waukegan, IL, ³AbbVie Inc., North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: As new treatment options for systemic lupus erythematosus (SLE) become available, understanding patient burden and preferences is key to optimizing shared decision-making. This study…
Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1514 • ACR Convergence 2025
Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
Yan Wang¹, Lulu Cao², Mengze Xu³, Jian Lu³, Jing He¹, Fanlei Hu⁴ and Zhanguo Li⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, ³State Key Laboratory of Protein and Plant Gene Research, Center for Bioinformatics, School of Life Sciences, Peking University, Beijing, China., Beijing, Beijing, China (People's Republic), ⁴Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits profound clinical and pathogenic heterogeneity, complicating diagnosis and treatment. Identifying subtype-specific biomarkers might intrinsically link to organ involvement.Methods: Patients…
Abstract Number: 1491 • ACR Convergence 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
julián Barahona-correa¹, Santiago Bernal-Macías², Daniel Fernandez³, Óscar Muñoz², Lucia Hernández⁴, Erika Susana Palacios Santillan⁵, Laura Maurelli⁶, Paula Alba⁷, Veronica Saurit⁸, Lucila Garcia⁹, María Emilia Sattler¹⁰, Maria Constanza Bertolaccini¹¹, Marina Laura Micelli¹², Graciela Gomez¹³, Micaela A. Cosatti¹⁴, Ana Carolina Ralle¹⁵, Joaquín Martinez Serventi¹⁶, Ana Silva¹⁷, ODIRLEI MONTICIELO¹⁸, Ángela Luzia Branco Pinto Duarte¹⁹, Laíssa Cristina Alves Alvino²⁰, Eduardo Borba²¹, Eloisa Bonfa²¹, Edgard dos Reis-Neto²², Iris Guerra Herrera²³, Milena Mimica²⁴, Gustavo Aroca Martínez²⁵, Lorena Gómez Escorcia²⁶, Carlos Alberto Cañas²⁷, Gerardo Quintana-Lopez²⁸, Carlos Toro-Gutierrez²⁹, José Maximiliano Martínez Pérez³⁰, Reyna Elizabeth Sánchez-Briones³¹, Mario Pérez Cristóbal³², Eduardo Martin-Nares³³, Yaneli Juarez-Vicuña³⁴, Ignacio García-Valladares³⁵, Rodrigo Ortiz Hernández³⁶, Jorge Antonio Esquivel Valerio³⁷, Maria Isabel Acosta³⁸, Astrid Paats³⁹, Jorge Cieza Calderón⁴⁰, Manuel Ugarte-Gil⁴¹, Armando Calvo⁴², Rodamin Ambiorix Alvarez Santana⁴³, Analía Cánepa⁴⁴, Carina Pizzarossa⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶ and Cristina Drenkard⁴⁷, ¹Colombian Association of Rheumatology (ASOREUMA), Bogotá, Colombia; Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, ²Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, ³Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁵Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁸Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁹Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ¹⁰Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, ¹¹Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹²Hospital J.M Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, ¹³Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁴CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno,’’ Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁵Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁶Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁷Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, ¹⁸Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁹Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, ²⁰Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²²Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²³Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²⁴Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁵Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ²⁶Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁷Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁸Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁹Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ³⁰Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³¹Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico City, Mexico, ³²Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁵Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, ³⁶Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto," San Luis Potosi, Mexico, San Luis Potosi, Mexico, ³⁷Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁸Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁹Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ⁴⁰Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴²Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴³Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴⁴Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁶Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁷Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA
Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…
Abstract Number: 1475 • ACR Convergence 2025
Humoral immune responses to real-world recombinant zoster vaccination in systemic lupus erythematosus
Arielle Mendel¹, Maximilien Lora², Sasha Bernatsky³, Paul Fortin⁴, Michaël Desjardins⁵, Joyce Rauch⁶, Chantal Sauvageau⁷, Evelyne Vinet³ and Ines Colmegna⁸, ¹McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁶McGill University, Hampstead, Canada, ⁷Institut national de santé publique du Québec, Quebec City, QC, Canada, ⁸The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for herpes zoster (HZ) and its complications. Exposure to immunosuppressants (IS) at the time…
Abstract Number: 1285 • ACR Convergence 2025
Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
Ganesh Ramanathan¹, Diana Valdes Cabrera², Oscar Mwizerwa³, Justine Ledochowski², Tala El Tal⁴, Sarah Mossad⁵, Ibrahim Mohamed¹, Joanna Law⁶, Lawrence Ng⁷, Paris Moaf², Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁸, Joan Wither⁹, Busisiwe Zapparoli¹⁰, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Etobicoke, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for neuropsychiatric involvement as disease onset typically occurs during the critical period of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].